Ceren DURMAZ ENGİN, Serap CİLAKER MIÇILI, Osman YILMAZ, Hüsnü Alper BAĞRIYANIK, Bekir Uğur ERGÜR, Fatoş ÖNEN, Ali Osman SAATCİ

Ocular toxicity of intravitreal golimumab in a rabbit model

Background/aim: To investigate the effect of intravitreal golimumab on rabbit retina histopathology. Materials and methods: Sixteen albino New Zealand rabbits were divided into three groups. The right eye of each rabbit in groups I, II, and III received a single intravitreal injection of 5 mg/0.05 mL 6 eyes , 10 mg/0.1 mL 6 eyes , or 20 mg/0.2 mL 4 eyes golimumab, while left eyes served as controls with the same volume of a balanced salt solution injection. All animals were examined using slit-lamp biomicroscopy and indirect ophthalmoscopy before and after intravitreal injection and at days 1 and 7. Animals were euthanized on day 7 and the eyes were enucleated for immunohistochemistry evaluation and electron microscopic examination of the retinas. Results: For groups I, II, and III, the number of cells in the outer nuclear layer and the inner nuclear layer was decreased compared to those in the control groups. In group I, the percentage of caspase-3 staining of the outer nuclear layer was significantly higher than that in the control. For groups II and III, TUNEL and caspase-3 staining percentages in the outer and inner nuclear layers were found to be significantly higher than those for the control groups. In the ganglion cell layer, for groups I, II, and III, neither TUNEL nor caspase-3 staining percentages showed any significant difference between two groups. No significant dose-dependent relationship was found for increasing doses of golimumab in all layers. Myelin figures and karyorrhexis in the photoreceptor cells were prominent in electron microscopy of the golimumab-injected eyes. Conclusion: Golimumab caused apoptosis in both photoreceptors and bipolar cells of the rabbit retina. Potential retinal toxicity of intravitreal golimumab should be considered if an intravitreal administration is planned.

Keywords:

Apoptosis, golimumab, intravitreal anti-TNF drugs, retina,

___

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104 (4): 487-501.
2. Myśliwiec M, Balcerska A, Zorena K, Myśliwska J, Lipowski P et al. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Research and Clinical Practice 2008; 79 (1): 141-146.
3. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Research 2001; 33 (5): 251-255.
4. Takase H, Futagami Y, Yoshida T, Kamoi K, Sugita S et al. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Investigative Ophthalmology & Visual Science 2006; 47 (4): 1557-1561.
5. Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxidative Medicine and Cellular Longevity 2016; 2016: 3164734.
6. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? The Annual Review of Immunology 2001; 19: 163-196.
7. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis & Rheumatology 2003; 48 (7): 2079-2080.
8. Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: A multicenter study. Ophthalmology 2014; 121 (10): 1877-1884.
9. Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behcet’s uveitis: a retrospective long-term follow-up study. Clinical and Experimental Rheumatology 2014; 32 (4 Suppl 84): S58-62.
10. Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H. Antitumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. Journal of Ophthalmic and Vision Research 2012; 7 (1): 39-44.
11. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30 (1): 71-80.
12. Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: A pilot study in 15 patients. American Journal of Ophthalmology 2012; 154 (3): 534-541.
13. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS et al. The use of intravitreal etanercept in diabetic macular oedema. Seminars in Ophthalmology 2007; 22 (2): 75-79.
14. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. American Journal of Ophthalmology 2009; 147 (5): 825-30.
15. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J et al. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010; 30 (10): 1601-1608.
16. Wu L, Fernando Arevalo J, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: Results of the Pan-American Collaborative Retina Study Group. International Ophthalmology 2012; 32 (3): 235-243.
17. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010; 2 (4): 428-439
18. EMA. Simponi 50 mg solution for injection in pre-filled pen: summary of product characteristics. Janssen Biologics B.V. Netherlands. Accessed 21 July 2018.
19. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Seminars in Arthritis and Rheumatism 2016; 46 (1): 95-101.
20. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocular Immunology and Inflammation 2014; 22 (2): 90-95.
21. Pascual-Camps I, Hernández-Martínez P, Monje-Fernández L, Dolz-Marco R, Gallego-Pinazo R et al. Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders. Journal of Ophthalmic Inflammation and Infection 2014; 4 (1): 1-5.
22. Kivilcim M, Peyman GA, Kazi AA, Dellacroce J, Ghobrial RN, Monzano R. Intravitreal toxicity of high-dose etanercept. Journal of Ocular Pharmacology and Therapeutics 2007; 23 (1): 57-62.
23. Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocular Immunology and Inflammation 2016; 24 (3): 319-326.
24. Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, ÁlvarezCastro C et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: A three-center experience. Mediators of Inflammation 2014; 2014: 717598.
25. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Investigative Ophthalmology & Visual Science 2008; 49 (3): 1151-1156.
26. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefe Archive for Clinical and Experimental Ophthalmology 2008; 246 (6): 907-911.
27. Fauser S, Kalbacher H, Alteheld N, Koizumi K, Krohne TU et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefe Archive for Clinical and Experimental Ophthalmology 2004; 242 (7): 582-586.
28. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G et al. Intravitreal administration of the antiTNF monoclonal antibody Infliximab in the rabbit. Graefe Archive for Clinical and Experimental Ophthalmology 2009; 247 (2): 273-281.
29. Melo GB, Moraes Filho MN, Rodrigues EB, Regatieri CV, Dreyfuss JL et al. Toxicity and retinal penetration of infliximab in primates. Retina 2012; 32 (3): 606-612.
30. Manzano RP, Peyman GA, Carvounis PE, Damico FM, Aguiar RG et al. Toxicity of high-dose intravitreal Adalimumab (Humira) in the rabbit. Journal of Ocular Pharmacology and Therapeutics 2011; 27 (4): 327-331.
31. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end‐ labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. Journal of Pathology 1993; 170 (1): 1-8.
32. Saraste Antti PK. Morphologic and biochemical hallmarks of apoptosis. Cardiovascular Research 2000; 45 (3): 528-537.
33. Harrison DJ. Counting apoptosis—why and how? Journal of Clinical & Molecular Pathology 1996; 49 (5): M245-6.
34. Duan WR, Gamer DS, Williams SD, Funckes-Shippy CL, Spath IS et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. Journal of Pathology 2003; 199 (2): 221-228.
35. Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell death and Differentiation 1999; 6 (6): 497-507.
36. de Boer RA, van Veldhuisen DJ, van der Wijk J, Brouwer RM, de Jonge N et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. Journal of Cardiac Failure 2000; 6 (4): 330-337.
37. de Paula ÁC, de Ávila MP, Isaac D, Salustiano R, de Lima A et al. Cytotoxicity and genotoxicity of intravitreal adalimumab administration in rabbit retinal cells. Arquivos Brasileiros de Oftalmologia 2015; 78 (2): 89-93.
38. Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα. Inflammatory Bowel Diseases 2013; 19(6): 1224-1231.
39. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Investigative Ophthalmology & Visual Science 2004; 45 (11): 4049-4059.
40. Martínez-Fernández de la Cámara C, Olivares-González L, Hervás D, Salom D, Millán JM et al. Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina. Journal of Neuroinflammation 2014; 11: 172.
41. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Investigative Ophthalmology & Visual Science 2007; 48 (4): 1773-1781.
42. Lucentis 10 mg/ml solution for injection: summary of product characteristics Novartis Pharm UK Ltd., Frimley, UK. Accessed 20 July 2019.
43. Damico FM, Gasparin F, Ioshimoto GL, Igami TZ, Cunha ASD Jr et al. Intravitreal injection of polysorbate 80: a functional and morphological study. Revista do Colégio Brasileiro de Cirurgiões 2017; 44 (6): 603-611.
44. Friedrich S, Cheng Y, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Current Eye Research 1997; 16 (7): 663-669.
45. del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. Experimental Eye Research 2015; 137: 111-124.
46. del Amo EM, Vellonen KS, Kidron H, Urtti A. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 215-226.
47. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Molecular Vision 2008; 14: 997-1005